No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
MRNS240816C2000
- 0.11
- +0.06+120.00%
15min DelayClose Jul 19 15:49 ET
0.11High0.09Low
0.09Open0.05Pre Close25 Volume38 Open Interest2.00Strike Price238.00Turnover175.99%IV47.55%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.11Extrinsic Value100Contract SizeAmericanOptions Type0.3182Delta0.5319Gamma13.00Leverage Ratio-0.0047Theta0.0002Rho4.14Eff Leverage0.0014Vega
Intraday
- 5D
- Daily
News
Express News | China National Medical Products Administration Has Approved Marinus Pharmaceuticals' Ganaxolone Oral Suspension For Epileptic Seizures In Patients Two Years Of Age And Older With CDKL5 Deficiency Disorder
Express News | Marinus Pharmaceuticals- in Marigold Trial, Ganaxolone Was Generally Well-Tolerated & Showed Safety Profile Consistent With Previous Clinical Trials
Express News | Marinus Pharmaceuticals Announces Ganaxolone Approved in China as First Treatment for Seizures Associated With Cdkl5 Deficiency Disorder
Ladenburg Thalmann Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating, Maintains Target Price $4
Ladenburg Thalmann analyst Michael Higgins maintains $Marinus Pharmaceuticals(MRNS.US)$ with a buy rating, and maintains the target price at $4.According to TipRanks data, the analyst has a success ra
Truist Financial Maintains Marinus Pharmaceuticals(MRNS.US) With Buy Rating
Truist Financial analyst Joon Lee maintains $Marinus Pharmaceuticals(MRNS.US)$ with a buy rating.According to TipRanks data, the analyst has a success rate of 48.3% and a total average return of 23.0%
Express News | Truist Securities Maintains Buy on Marinus Pharma, Maintains $10 Price Target
Comments
$Marinus Pharmaceuticals(MRNS.US$ China National Medical Products Administration Has Approved Marinus Pharmaceuticals' Ganaxolone Oral Suspension For Epileptic Seizures In Patients Two Years Of Age And Older With CDKL5 Deficiency Disorder
$Marinus Pharmaceuticals(MRNS.US$ Marinus Pharmaceuticals- in Marigold Trial, Ganaxolone Was Generally Well-Tolerated & Showed Safety Profile Consistent With Previous Clinical Trials
$Marinus Pharmaceuticals(MRNS.US$ Marinus Pharmaceuticals Inc: Failed to Achieve Statistical Significance on Second Co-Primary Endpoint
Marinus Pharmaceuticals Inc: Raise Trial Met Its First Co-Primary Endpoint
Marinus Expects Phase 3 Trusttsc Data in Q4 2024
Marinus Pharmaceuticals Inc: Raise Trial Met Its First Co-Primary Endpoint
Marinus Expects Phase 3 Trusttsc Data in Q4 2024
1
$Marinus Pharmaceuticals(MRNS.US$ Topline data from the TrustTSC trial is anticipated in the first half of the fourth quarter of 2024. Marinus is targeting submission of a supplemental New Drug Application to the U.S. Food and Drug Administration in April 2025 with priority review requested.
2
2
$Marinus Pharmaceuticals(MRNS.US$ Marinus Pharmaceuticals Inc: Enrollment Complete in Phase 3 Trusttsc Trial With Topline Data Anticipated in First Half of Q4 2024
Read more